Ocular Therapeutix (OCUL) Reports Q4 Revenues Below Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ocular Therapeutix (OCUL) PT Raised to $22 at Cantor Fitzgerald; 'Preparing for a Momentous 2018'
March 8, 2018 10:42 AM ESTCantor Fitzgerald analyst Elemer Piros raised his price target on Ocular Therapeutix (NASDAQ: OCUL) to $22.00 (from $21.00) while maintaining a Overweight rating, saying the company is preparing for a 'momentous 2018'.
Piros commented, "Ocular hosted a conference call to review its quarterly progress and... More
